Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | PARP1 | P09874 | 4/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.45 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.45 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29908864 | 0.86 | KDM4E (0.51) | ALDH1A1PARP1KMT2AMAPTKDM4E | |
| SCHEMBL15328054 | 0.83 | MAPK1 (0.43) | ALDH1A1PARP1CA1CA2LMNA | |
| SCHEMBL1396731 | 0.81 | MAPK1 (0.58) | ALDH1A1PARP1PARP2LMNAMAPT | |
| SCHEMBL7735518 | 0.81 | ALDH1A1 (0.56) | ALDH1A1LMNAKMT2AMAPTKDM4E | |
| SCHEMBL15327933 | 0.80 | MAPK1 (0.54) | ALDH1A1PARP1CA1CA2PARP2 | |
| SCHEMBL1161158 | 0.80 | TYK2 (0.50) | ALDH1A1LMNAMEN1KMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL29908833 | 0.80 | MAPK1 (0.56) | ALDH1A1PARP1PARP2LMNAMAPT | |
| Hydrochloric Acid SCHEMBL23071632 | 0.79 | TYK2 (0.49) | ALDH1A1LMNAMEN1KMT2AKDM4E | |
| SCHEMBL15327967 | 0.78 | KDM4E (0.63) | ALDH1A1PARP1LMNAMEN1KMT2A | |
| SCHEMBL30174215 | 0.77 | KDM4E (0.45) | ALDH1A1PARP1PARP2KDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111295386-B | Thienopyridine derivatives and pharmaceutical compositions containing the same | 伟迈可生物有限公司 | 2022-09-06 | — | — | CN | claimed |
| EP-2838531-B1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ANNJI PHARM CO LTD (CN) | 2016-09-21 | — | — | EP | claimed |
| US-8946282-B2 | Indolin-2-one derivatives as protein kinase inhibitors | Annji Pharmaceutical Co., Ltd. (TW) | 2015-02-03 | — | — | US | claimed |
| US-20130281451-A1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Annji Pharmaceutical Co., Ltd. (TW) | 2013-10-24 | — | — | US | claimed |
| CN-116685324-A | Pharmaceutical composition for preventing or treating pancreatic cancer associated with RON mutation and method of using the same | 伟迈可生物有限公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-116390729-A | Pharmaceutical composition for preventing or treating non-small cell lung cancer associated with RON mutation and method of using the same | 伟迈可生物有限公司 | 2023-07-04 | — | — | CN | disclosed |
| CN-115916210-A | Pharmaceutical composition for preventing or treating small cell lung cancer associated with RON mutation and method of using the same | 伟迈可生物有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115209900-A | Pharmaceutical composition for preventing or treating cancer in which KRAS mutation and activated RON are present | 伟迈可生物有限公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-115003307-A | Pharmaceutical composition for preventing or treating cancers associated with KRAS mutations | 伟迈可生物有限公司 | 2022-09-02 | — | — | CN | disclosed |
| EP-2838531-B1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ANNJI PHARM CO LTD (CN) | 2016-09-21 | — | — | EP | disclosed |
| US-8946282-B2 | Indolin-2-one derivatives as protein kinase inhibitors | Annji Pharmaceutical Co., Ltd. (TW) | 2015-02-03 | — | — | US | disclosed |
| US-20130281451-A1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Annji Pharmaceutical Co., Ltd. (TW) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281451-A1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ING2, CDK2, MAP3K20 | ALDH1A1 3369/4885PARP1 1013/4885CA1 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.